RPRX

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.

Wall Street analysts forecast RPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX is 43.80 USD with a low forecast of 38.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Royalty Pharma PLC revenue for the last quarter amounts to 609.29M USD, increased 7.90 % YoY.

Royalty Pharma PLC. EPS for the last quarter amounts to 0.67 USD, decreased -44.63 % YoY.

Royalty Pharma PLC (RPRX) has 99 emplpoyees as of December 16 2025.

Today RPRX has the market capitalization of 22.24B USD.